Lixte Biotechnology Holdings, Inc. (LIXT) Stock Price & Analysis
Lixte Biotechnology Holdings, Inc. (LIXT) rose 3.31% to USD 6.87 as of June 10, 2026 at 03:10 UTC, according to Nexqual real-time market data.
LIXT last closed at USD 6.65; the session ranged USD 6.76–7.34 on volume of 254,428 shares. Market capitalization is $119.44M, with a 52-week range of USD 0.64–7.5 (NCM). Source: Nexqual, June 10, 2026 at 03:10 UTC.
Key Statistics (as of June 10, 2026 at 03:10 UTC)
| Price | USD 6.87 |
|---|---|
| Change | ▲ 3.31% (up) |
| Previous Close | USD 6.65 |
| Open | USD 6.8 |
| Day Range | USD 6.76 – 7.34 |
| 52-Week Range | USD 0.64 – 7.5 |
| Volume | 254,428 shares |
| Market Cap | $119.44M |
| Exchange | NCM |
Technical Analysis (LIXT)
Nexqual's technical model rates LIXT "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 03:10 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 64.67 (neutral) |
| vs SMA50 | Above (USD 4.53) |
| MACD | 0.71 (positive) |
Analyst Ratings (LIXT)
Wall Street analysts rate LIXT "None", per Nexqual as of June 10, 2026 at 03:10 UTC.
| Consensus Rating | None |
|---|
Earnings (LIXT)
Source: Nexqual, June 10, 2026 at 03:10 UTC.
Financials & Fundamentals (LIXT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -101.95% |
| Debt / Equity | 9.44 |
| Current Ratio | 3.88 |
| Total Cash | $5.11M |
| Total Debt | $1.03M |
| Free Cash Flow | $-1.28M |
Source: Nexqual, June 10, 2026 at 03:10 UTC.
Financial Health Score (LIXT)
Nexqual rates Lixte Biotechnology Holdings, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:10 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Strong — $5M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$3M |
| Efficiency | Critical — ROE -102%, ROA -46.0% |
Ownership (LIXT)
| Insider Ownership | +4.47% |
|---|---|
| Institutional Ownership | +6.89% |
| Shares Outstanding | 17.39M |
| Float | 11.11M |
| Short % of Float | +0.21% |
Source: Nexqual, June 10, 2026 at 03:10 UTC.
Leadership (LIXT)
Lixte Biotechnology Holdings, Inc. is led by Geordan G. Pursglove (age 37), CEO, President & Chairman, per Nexqual as of June 10, 2026 at 03:10 UTC.
| CEO, President & Chairman | Geordan G. Pursglove (age 37) |
|---|---|
| Chief Financial Officer | Peter M. Stazzone (age 73) |
| Chief Scientific Officer | Bastiaan van der Baan M.Sc. (age 53) |
Major Backers & Investors (LIXT)
Notable institutional backers of Lixte Biotechnology Holdings, Inc. include Scotia Capital Inc., Renaissance Technologies, Federation Des Caisses Desjardins Du Quebec, according to Nexqual as of June 10, 2026 at 03:10 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Scotia Capital Inc. | 1.89% |
| Renaissance Technologies | 0.62% |
| Federation Des Caisses Desjardins Du Quebec | 0.43% |
| Citadel | 0.38% |
| Fidelity | 0.31% |
| Ethos Financial Group, LLC | 0.17% |
| Xtx Topco Ltd | 0.16% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.89% |
| Geode Capital | 0.39% |
| State Street | 0.12% |
Source: Nexqual, June 10, 2026 at 03:10 UTC.
From Lixte Biotechnology Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Liora's proprietary technology, known as LiGHT System (Linac for Image Guided Hadron Therapy), has significant advantages over currently available technologies for treating tumors with proton therapy.
- The Company's ability to stop third parties from making, using, selling, offering to sell, or importing our technology may depend on the extent to which the Company has rights under valid and enforceable licenses, patents, or trade secrets that cover these activities.
Partnerships
- We completed the enrollment of the first 21 patients in Q4, 2025 and expect patient 22 to be enrolled in Q1 2026.   Netherlands Cancer Institute Clinical Trial   Effective June 10, 2024, we entered into a Clinical Trial Agreement with the Netherlands Cancer Institute ("NKI") to conduct a Phase 1b clinical trial of the Company's protein phosphatase inhibitor, LB-100, combined with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F.
- Because of the large footprint and high price of many proton therapy systems, there is increasing demand for the development of smaller, more compact proton therapy systems.     Facilities   Liora's equipment and operations are located in part of the Tower at Daresbury Laboratory, Daresbury Cheshire, United Kingdom, pursuant to a lease agreement with the United Kingdom Research and Innovation.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| ABVC | ABVC Biopharma, Inc. | USD 1.32 | ▼ 0.75% |
| BBLG | Bone Biologics Corp | USD 1.23 | ▼ 1.52% |
| PALI | Palisade Bio, Inc. | USD 1.69 | ▼ 2.87% |
| KPRX | Kiora Pharmaceuticals, Inc. | USD 2.59 | ▲ 3.6% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:10 UTC. This page is informational and not investment advice.